Breaking Down SG&A Expenses: Bio-Techne Corporation vs Alpine Immune Sciences, Inc.

A Comparative Analysis of SG&A Expenses in the Biotech Sector

In the dynamic world of biotechnology, understanding financial trends is crucial for investors and stakeholders. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent biotech companies: Bio-Techne Corporation and Alpine Immune Sciences, Inc., from 2014 to 2023.

Bio-Techne Corporation, a leader in the industry, has consistently shown a robust increase in SG&A expenses, peaking at approximately $397 million in 2024. This represents a staggering 554% increase from 2014, reflecting its aggressive expansion and investment in administrative capabilities.

Conversely, Alpine Immune Sciences, Inc. has experienced a more modest growth trajectory. Starting at around $2.3 million in 2014, their SG&A expenses rose to $22 million by 2023, marking a tenfold increase. This growth underscores their strategic scaling efforts in a competitive market.

The data for 2024 is incomplete for Alpine Immune Sciences, Inc., highlighting the need for ongoing analysis to capture the full financial picture.